A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Research

Executive Summary: A 83-01 is a small-molecule inhibitor that selectively targets the TGF-β type I receptor ALK-5 and related receptors ALK-4/ALK-7, displaying an IC₅₀ of ~12 nM against ALK-5-mediated Smad signaling (Saito et al., 2025). It demonstrates robust inhibition of TGF-β-induced transcription in Mv1Lu cellular assays, with 68% activity reduction at 1 μM. A 83-01 shows negligible inhibition of BMP-induced signaling at 1 μM, confirming pathway selectivity. The compound is widely used for studying EMT, organoid maturation, and cellular growth suppression. APExBIO supplies A 83-01 (A3133) with validated solubility and storage guidelines (product page).

Biological Rationale

The TGF-β pathway is central to cell fate regulation, tissue homeostasis, and disease mechanisms. Signaling via type I receptors (ALK-5, ALK-4, ALK-7) activates Smad2/3 transcription factors, affecting processes such as proliferation, differentiation, and EMT (Saito et al., 2025). Dysregulation of TGF-β signaling is implicated in cancer progression, fibrosis, and impaired tissue regeneration. Inhibitors like A 83-01 enable precise modulation of this pathway, allowing researchers to dissect causal relationships in complex systems such as organoids and in vitro disease models. Compared to generic kinase inhibitors, A 83-01 provides specificity for ALK-5/4/7 with minimal off-target effects on the BMP axis at working concentrations.

Mechanism of Action of A 83-01

A 83-01 (3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide) binds competitively to the ATP-binding pocket of ALK-5, ALK-4, and ALK-7, inhibiting receptor-mediated phosphorylation of Smad2/3. The inhibition is concentration-dependent, blocking downstream transcriptional activation in a specific manner (Saito et al., 2025). At 1 µM, A 83-01 achieves 68% inhibition of TGF-β-induced luciferase reporter activity in Mv1Lu cells. The selectivity profile indicates little effect on BMP4-induced transcription at concentrations ≤1 μM, with partial suppression only at higher doses (>3 μM) in C2C12 cells. Its physicochemical properties include a molecular weight of 421.52, high solubility in DMSO (>21.1 mg/mL), and insolubility in water.

Evidence & Benchmarks

• A 83-01 inhibits ALK-5-mediated, TGF-β-induced Smad-dependent transcription with an IC₅₀ of ~12 nM in cellular assays (Saito et al., 2025).
• At 1 μM, A 83-01 reduces luciferase reporter activity by 68% in Mv1Lu cells stimulated with TGF-β (Saito et al., 2025).
• No significant effect is observed on BMP-induced transcription at 1 μM in C2C12 cells, confirming selectivity (Saito et al., 2025).
• A 83-01 is widely utilized to maintain stemness in human induced pluripotent stem cell-derived intestinal organoids by inhibiting differentiation during expansion phases (Saito et al., 2025).
• Solubility is confirmed at >21.1 mg/mL in DMSO and >9.82 mg/mL in ethanol with warming and ultrasonic treatment, but A 83-01 is insoluble in water (APExBIO).
• Storage of the dry powder at -20°C and DMSO stock at ≤-20°C preserves activity for several months, with long-term storage not recommended (APExBIO).

Applications, Limits & Misconceptions

A 83-01 is extensively used in:

• EMT and Cellular Growth Inhibition Studies: It blocks TGF-β-induced EMT, a critical step in cancer metastasis and fibrosis models.
• Stem Cell and Organoid Research: It supports the expansion and maintenance of stem cell populations in 3D intestinal organoid cultures, suppressing premature differentiation (Saito et al., 2025).
• Cancer Biology: Used to dissect the role of TGF-β signaling in tumor proliferation and microenvironment remodeling.
• Fibrosis and Regeneration: Facilitates study of TGF-β-driven fibrotic responses in tissue models.

For deeper perspectives on translational and mechanistic aspects, see A 83-01: Transforming TGF-β Inhibition for Cancer and Reg... (this article details the role in cancer and regenerative settings), and A 83-01 and the Future of Organoid Engineering: Strategic... (which provides strategic guidance for scalable organoid models; the present article clarifies precise selectivity and storage aspects not covered there). For a comprehensive mechanistic focus, A 83-01: Precision Disruption of TGF-β Signaling for Tran... is recommended, while this article updates on recent application benchmarks.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: A 83-01 does not broadly inhibit all serine/threonine kinases and is selective for ALK-5/4/7 at recommended concentrations.
• Limited BMP pathway inhibition: At ≤1 μM, it does not significantly affect BMP-induced transcription; partial suppression may occur only above 3 μM.
• Not water-soluble: Attempts to dissolve in aqueous buffers result in precipitation; only DMSO or ethanol (with heating/sonication) are suitable solvents.
• Long-term DMSO stock instability: Solutions in DMSO should be stored at ≤-20°C and used within a few months; avoid repeated freeze-thaw cycles.
• Not suitable for direct in vivo use: A 83-01 is a research reagent with no established pharmacokinetic or toxicology profiles for animal/human administration.

Workflow Integration & Parameters

• Preparation: Dissolve A 83-01 powder in DMSO to yield a stock concentration (e.g., 10 mM); use ultrasonic treatment or gentle heating if needed (APExBIO).
• Working Concentration: Typical in vitro working range is 0.1–1 μM for pathway inhibition; higher concentrations may affect selectivity.
• Storage: Store dry at -20°C; DMSO stocks at ≤-20°C; avoid exposure to light and moisture.
• Controls: Include vehicle (DMSO-only) and, where relevant, BMP pathway controls to assess specificity.
• Model Systems: Effective in Mv1Lu, C2C12, and human iPSC-derived organoid cultures. Refer to published protocols for time-course and dosing guidance (Saito et al., 2025).

For product-specific technical details and batch documentation, refer to the A 83-01 product page (A3133) by APExBIO.

Conclusion & Outlook

A 83-01 is a validated, selective inhibitor of TGF-β type I receptors, enabling precise dissection of Smad-dependent transcription and cellular fate in advanced research models. Its defined selectivity, solubility, and storage parameters support reproducible results in EMT, organoid, and cancer biology research. Future protocols may expand its applications in regenerative medicine and tissue engineering. For advanced workflow design, practitioners are encouraged to cross-reference recent organoid engineering strategies (A 83-01 and the Future of Organoid Engineering) and mechanistic studies (Precision Disruption of TGF-β Signaling), while this article provides updated selectivity, use-limitations, and integration benchmarks for A 83-01.